Novartis gets FDA approval for expanded use of Tasigna

06/17/2010 | Wall Street Journal, The

The FDA authorized Novartis to promote Tasigna as a treatment for adults in earlier stages of Philadelphia chromosome-positive chronic myeloid leukemia. The drug was approved in October 2007 for patients whose disease had progressed or who failed to respond to other treatments, including Novartis' Gleevec.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA